Aethlon Medical, Inc. (AEMD)
Chart Events
Performance Outlook
| Previous Close | 0.3760 |
| Open | 0.3735 |
| Bid | 0.3601 x 1000 |
| Ask | 0.3850 x 900 |
| Day's Range | 0.3735 - 0.3850 |
| 52 Week Range | 0.2300 - 2.4600 |
| Volume | |
| Avg. Volume | 1,008,635 |
| Market Cap | 8.777M |
| Beta (5Y Monthly) | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks Small Cap Research
AEMD: New CRO to Help Advance Studies; Expanded Team to Facilitate Efforts
By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT New CRO to facilitate study of the Hemopurifier® in a range of cancers To advance its medical device, the HemoPurifier®, through clinical studies towards potential regulatory approval and commercialization, Aethlon Medical’s (NASDAQ:AEMD) has launched several recent initiatives. Among other steps, the company has: ▪ Embarked on launching
- PR Newswire
Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update
Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2022 and provided an update on recent developments.
- PR Newswire
Aethlon Medical to Present at Sequire Biotechnology Conference on February 2nd, 2023
Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, announced today that it will be presenting virtually at the upcoming Sequire Biotechnology Conference on Thursday, February 2nd, at 10:00 AM ET. Steven LaRosa, M.D., Chief Medical Officer and Chief Scientific Officer of Aethlon Medical, will be giving the presentation.
